News

October 29th, 2020

 

Mebias Discovery Receives Grant from NIDA to Advance MEB1170 as an Analgesic Drug Candidate for the Prevention and Treatment of Opioid Use Disorder

October 14th, 2019

 

Mebias Discovery Raises $3.5 Million to Expand Pipeline Using a Novel, Cell
Signaling-Pathway Selective GPCR Drug Discovery Platform

July 19th, 2019

Philadelphia biopharm firm developing a new type of pain medicine raises $3.5M

September 15th, 2018

 

MEBIAS Discovery Receives Grant from NIDA to Advance Its Signaling-Pathway Selective Mu-Opioid Receptor Drug Candidate

April 4th, 2018

 

NIH launches HEAL Initiative, doubles funding to accelerate scientific solutions to stem national opioid epidemic

December 5th, 2017

 

‘Biased’ opioids could yield safer pain relief

New compounds activate opioid receptor in a way that protects breathing

October 19th, 2017

 

Mebias’ mu opioids best morphine, Trevena drug in preclinical studies

October 16th, 2017

 

MEBIAS Discovery LLC Presents Pre-Clinical Data on Mu Opioid Receptor Pain Compounds at ADDC